TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02117921

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One-on-one interview and educational sessions. Reading material for educational series provided.
Description: A one-on-one interview with the patient and the principal investigator and group educational sessions.
Study: NCT02604498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemonoxacin
Description: Single dose 500mg oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemonoxacin
Description: Single dose 500mg oral
Study: NCT02726906

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate-aerobic walking

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Positron Emission Tomography (PET) scan
Description: Radioligand that binds to proteins using a PET/CT scanner.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET) scan
Description: Radioligand that binds to proteins using a PET/CT scanner.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Healthy living education

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Physical activity monitor
Description: Wrist device that will track daily physical activity

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Physical activity monitor
Description: Wrist device that will track daily physical activity
Study: NCT03660189

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Two bag system
Description: The two IV fluid bags have identical fluids and electrolytes, except one has 10% dextrose and the other has no dextrose. The two fluid bags run simultaneously and their rates are adjusted according to the patient's blood sugar.
Study: NCT03448575

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control - Provider Medication Alert Only
Description: Simple text medication alert referencing Choosing Wisely guidelines.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention - Alert + CAP Review AND Enhanced BH Access
Description: Interactive medication alert referencing SUAY Clinical Guidelines and offering options to keep/remove orders for the antipsychotic, virtual CAP consult, BH navigation for the patient, and access to bridging therapy for the patient.
Study: NCT00959959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOK-001
Description: 8 capsules (325 mg each), split dose (4 capsules with breakfast, 4 capsules with dinner)
Study: NCT03051256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REL-1017
Description: REL-1017 will be administered as an oral solution. Patients will continue to take the same, stabilized antidepressant medication that they were taking at screening throughout the course of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REL-1017
Description: REL-1017 will be administered as an oral solution. Patients will continue to take the same, stabilized antidepressant medication that they were taking at screening throughout the course of the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as an oral solution. Patients will continue to take the same, stabilized antidepressant medication that they were taking at screening throughout the course of the study.
Study: NCT05178355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KVD824
Description: Active

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KVD824
Description: Active
Study: NCT03798301

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMV-specific T-cells
Description: Naturally occurring, allogeneic donor lymphocytes derived from a leukapheresis or a whole blood product, enriched for CMVspecific CD4+ and CD8+ T-cells
Study: NCT03910452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: 3 days of IV Busulfan. An alkylating chemotherapeutic agent determined to have broad myelosuppressive effects. On this study is being used as part of conditioning regimen for myelosuppressive properties as per package insert and standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: 5 days of IV Alemtuzumab. A humanized monoclonal antibody directed against CD52 (which is abundantly expressed on all human lymphocytes), and causes T cell activation in vitro as well as complement-mediated lysis and antibody-dependent cellular toxicity. For this study, being used as part of the conditioning regimen per package insert and standard of practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 2 days of IV Cyclophosphamide. This is an antineoplastic, and for this study is bine used for its immunosuppressive mechanism of action per package insert and standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Post Peripheral blood stem cell infusion. It is used for its immunosuppressive mechanism of action.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: 2 fractionated doses on -2 day. It is used for its immunosuppressive mechanism of action. It is SOP for conditioning for transplant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic peripheral blood stem cell
Description: IV infused donor peripheral blood stem cell. Stem cells are cells that give rise to the blood cells - red blood cells that carry oxygen, white blood cells that help the body to fight infections, and platelets that help make the blood clot. Collected and infused per the standard of operating procedures established by the Department of Transfusion Medicine.
Study: NCT02954692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INSULIN GLARGINE (U300)
Description: Pharmaceutical form: pen for injection~Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sulfonylurea
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: meglitinides
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiazolidinediones
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alpha-glucosidase inhibitors
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP1 Receptor Agonist
Description: Pharmaceutical form: pen for injection~Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dipeptidyl peptidase-IV (DPP-IV) inhibitors
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium-glucose transport-2 (SGLT-2) inhibitors
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT05437874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natural Water
Description: 355 ml of regular coke, diet coke or mineral water should be drunk.~* Salivary pH will be determined at 0, 5, 10, 15, 30, 45 and 60 minutes later~* Dental biofilm pH will be determined at 0, 5, 10, 15, 30, 45 and 60 minutes later~* Streptococcus mutans dental biofilm formation ( Colony Forming Units) will be conducted at 0 and 120 minutes later

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Natural Water
Description: 355 ml of regular coke, diet coke or mineral water should be drunk.~* Salivary pH will be determined at 0, 5, 10, 15, 30, 45 and 60 minutes later~* Dental biofilm pH will be determined at 0, 5, 10, 15, 30, 45 and 60 minutes later~* Streptococcus mutans dental biofilm formation ( Colony Forming Units) will be conducted at 0 and 120 minutes later

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Natural Water
Description: 355 ml of regular coke, diet coke or mineral water should be drunk.~* Salivary pH will be determined at 0, 5, 10, 15, 30, 45 and 60 minutes later~* Dental biofilm pH will be determined at 0, 5, 10, 15, 30, 45 and 60 minutes later~* Streptococcus mutans dental biofilm formation ( Colony Forming Units) will be conducted at 0 and 120 minutes later

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natural Water
Description: 355 ml of regular coke, diet coke or mineral water should be drunk.~* Salivary pH will be determined at 0, 5, 10, 15, 30, 45 and 60 minutes later~* Dental biofilm pH will be determined at 0, 5, 10, 15, 30, 45 and 60 minutes later~* Streptococcus mutans dental biofilm formation ( Colony Forming Units) will be conducted at 0 and 120 minutes later
Study: NCT00922506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxazosin plus tolterodine SR
Description: doxazosin plus tolterodine SR(2 mg, qd)for 12 weeks or (4 mg, qd) for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxazosin plus tolterodine SR
Description: doxazosin plus tolterodine SR(2 mg, qd)for 12 weeks or (4 mg, qd) for 12 weeks
Study: NCT01399047

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: The liquid dosage will be individualized, contingent upon the subject's weight. Subjects will receive 50% of the target dose (300mg/m2/dose BID) during Week 0-Week 2, then increase to the full dose (600mg/m2/dose BID) in Week 3, continuing at this dose through Week 8. Additionally, due to the risk of gastrointestinal disturbance (hemorrhage, ulcer), children will also receive prophylactic Prilosec (Omeprazole) for the duration of the study, during both the mycophenolate and placebo arms.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Liquid Placebo
Description: The dosage will be individualized, contingent upon the subject's weight. Subjects will receive 50% of the target dose (300mg/m2/dose BID) during Week 0-Week 2, then increase to the full dose (600mg/m2/dose BID) in Week 3, continuing at this dose through Week 8. Additionally, due to the risk of gastrointestinal disturbance (hemorrhage, ulcer), children will also receive prophylactic Prilosec (omeprazole) for the duration of the study, during both the mycophenolate and placebo arms.
Study: NCT02364323

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Risk Counselling
Description: Motivational message- towards lifestyle change, improved compliance and risk factors control Review overall control of clinical risk factors based on lab test results

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal usual care
Description: General education on diabetes and diabetic complications
Study: NCT02729363

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Relaxation video clip
Description: This intervention is a 12-minute guided audio-visual relaxation intervention.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Sickle Cell Disease Experience Discussion
Description: This intervention is a 12-minute computer-administered sickle cell disease experience discussion.
Study: NCT01986127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: single intralesional administration during endoscopy process

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: single intralesional administration during endoscopy
Study: NCT05509465

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ergonomic chinrest
Description: The novel ergonomic chinrest (Kréddle®, Wyoming, US) is fully adjustable to accommodate each violinist's body type and performance style: regarding height, rotation and tilting.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ergonomic chinrest used with a low Super Kun shoulder rest
Description: The novel ergonomic chinrest (Kréddle®, Wyoming, US) is fully adjustable to accommodate each violinist's body type and performance style: regarding height, rotation and tilting. The low Super Kun shoulder rest has been adjusted to be in the lowest position for all legs attached to the violin before the violinists received it. All participants was told not to adjust the shoulder rest but adjust the chinrest.
Study: NCT03196661

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Influenza A (H7N9) virus vaccine
Description: To prevent the infection of H7N9 virus.
Study: NCT05178355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KVD824
Description: Active
Study: NCT05178355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KVD824
Description: Active

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KVD824
Description: Active

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KVD824
Description: Active
Study: NCT02492555

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SI
Description: A routine scheduled (SI) screening of FC and DA every 3rd month

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OD
Description: A screening of FC and DA on demand (OD)
Study: NCT04598854

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intravascular laser irradiation of blood
Description: Low intensity intravascular laser irradiation of blood phototherapy is a method of a 632.8 nm red light penetrate into a vein through fiber and the brightness is 100 fold of the sun. The light accelerates blood and cells circulation in the human body, so that protein molecular structure would promote changes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Intravascular laser irradiation of blood (Sham)
Description: zero intensity of the laser energy
Study: NCT02421666

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PNMI
Description: Eligible patients received patient navigator led plus mobile phone text messaging intervention (PNMI) or standard care. Bilingually trained patient navigators were recruited from our existing patient navigator training network, received intensive training on HBV prevention, diagnosis and treatment management, and served as a liaison with respective clinical partners. The PNMI intervention offered three education sessions on HBV management and weekly CHB patient-designed educational phone-based text messages for five weeks.
Study: NCT00255346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib (BMS-354825)
Description: 70 mg orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib (BMS-354825)
Description: 70 mg orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib (BMS-354825)
Description: 70 mg orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib (BMS-354825)
Description: 70 mg orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib (BMS-354825)
Description: 70 mg orally twice daily
Study: NCT02378558

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MagneMarker
Description: The MagneMarker system includes a magnetic clip the MagneMarker, a clip placement device the MagneJector, and a magnetic field detecting probe the MagneProbe. The MagneMarker and MagneJector are used by a radiologist during a breast localization procedure. The MagneProbe is used by a surgeon to locate the MagneMarker during breast excision.
Study: NCT04269018

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cancer specific Mobile text message
Description: The intervention is cancer specific lifestyle mobile text messages daily for 2 months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General health messages
Description: Daily text related with general health message
Study: NCT02093663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMX Mesalamine/Mesalazine (Low Dose)
Description: Once daily, tablets - the amount depends on the participants weight; 900 milligram per day (mg/day) for participants weighing 18 kg to less than or equal to (\<=) 23 kilograms (kg); 1200 mg/day for participants weighing greater than (\>) 23 kg to \<= 35 kg; 1800 mg/day for participants weighing \> 35 kg to \<= 50 kg; 2400 mg/day for participants weighing \> 50 kg to \<= 90 kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMX Mesalamine/Mesalazine (High Dose)
Description: Once daily, tablets - the amount depends on the participants weight;1800 mg/day for participants weighing 18 kg to \<= 23 kg; 2400 mg/day for participants weighing \> 23 kg to \<= 35 kg; 3600 mg/day for participants weighing \> 35 kg to \<= 50 kg; 4800 mg/day for participants weighing \> 50 kg to \<= 90 kg.
Study: NCT01373216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Perioperative continuous i.v. administration of exenatide lasting for 72 hours - 40 ng/min for initial 30 min, 20 ng/min for remaining 71.5 hours
Study: NCT03793465

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: tart cherry concentrate
Description: Consume 2 servings (1 ounce or 2 tablespoon/serving) per day for three days before cardiac surgery
Study: NCT02636569

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topical diclofenac daily
Description: Topical diclofenac will be applied daily for 30 days. Each subject will be seen for a screening visit as well as a baseline visit and a visit at month 1. As part of the study small biopsies will be taken from three locations at the baseline visit. The biopsy will be taken from one actinic keratosis, one sun exposed area and one not sun exposed area. A biopsy is a small surgical procedure where a small piece of your skin is removed.~After applying the medications for 30 days you will return to the clinic for your 30 day visit. At this visit you will again have three biopsies taken; one AK, one sun exposed, and one non sun exposed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo Each subject will be seen for a screening visit as well as a baseline visit and a visit at month 1. As part of the study small biopsies will be taken from three locations at the baseline visit. The biopsy will be taken from, one actinic keratosis, one area that is typically exposed to the sun as well as a site that is typically protected from sun light. A biopsy is a small surgical procedure where a small piece of your skin is removed.~After applying the medications for 30 days you will return to the clinic for your 30 day visit. At this visit you will again have two biopsies taken. One of these biopsies will be from the skin on your arm that was treated with medication for the prior 30 days, and the other biopsy will be from a site that typically is not exposed to the sun.
Study: NCT04715399

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT00864708

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: radio frequency-controlled (RF) Microstimulator (RFM) Gait System
Description: Fully Implanted FES system to assist patient with gait component practice
Study: NCT05178355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KVD824
Description: Active

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KVD824
Description: Active

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KVD824
Description: Active

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KVD824
Description: Active

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KVD824
Description: Active

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KVD824
Description: Active

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KVD824
Description: Active
Study: NCT03010462

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nexstim NBS guided active rTMS
Description: Nexstim NBS guided active rTMS + standardized task-oriented therapy

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Nexstim NBS guided sham rTMS
Description: Nexstim NBS guided sham rTMS + standardized task-oriented therapy
Study: NCT05178355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KVD824
Description: Active

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to KVD824
Description: Placebo
Study: NCT01198288

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: domiciliary rehabilitation
Description: a respiratory rehabilitation programme at the patient home
Study: NCT02206464

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-FLUDNA071-00-VP
Description: H7 DNA Vaccine
Study: NCT01198288

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: As describe in the standard care arm
Study: NCT05178355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to KVD824
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to KVD824
Description: Placebo
Study: NCT01826890

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NAVA Technology
Description: Use of NAVA technology: Diaphragmatic monitoring and NAVA ventilation mode
Study: NCT02643797

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medical Assistant Health Coaching
Description: One-on-one behavioral health screening and tailored intervention by the MA health coach with patients who have type 2 diabetes.
Study: NCT03417089

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Falciform ligament suspension
Description: routine of falciform ligament suspension during Mini gastric bypass

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: no suspension
Description: working without of falciform ligament suspension during Mini gastric bypass
Study: NCT02206464

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-FLUDNA071-00-VP
Description: H7 DNA Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-FLUDNA071-00-VP
Description: H7 DNA Vaccine
Study: NCT05178355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to KVD824
Description: Placebo
Study: NCT04529785

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SVC only
Description: Patients allocated to this arm will receive an RF ablation with the isolation of the SVC alone

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SVC isolation with substrate modification and vein of Marshal ethanol infusion
Description: Patients allocated to this arm will receive an RF ablation with the isolation of the SVC, substrate modification and vein of Marshal ethanol infusion
Study: NCT03694964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ProteoCIT®
Description: 30 patients will be randomized into the group that will receive 10 mg of citrulline and 30 patients will be randomized into the placebo group for 45 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: 30 patients will be randomized into the group that will receive 10 mg of citrulline and 30 patients will be randomized into the placebo group for 45 days
Study: NCT02799472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3196165
Description: GSK3196165 is supplied as liquid and will be administered as SC injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% weight by volume (w/v) sodium chloride solution administered as SC injection.